Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02453087 · ClinicalTrials.gov registry record · Phase 1

A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

A Phase 1 study of Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 1
Development phase
66
Enrollment target
7
Study locations

NCT02453087 is a Phase 1 study of Non-Hodgkin's Lymphoma that has completed, run by Hoffmann-La Roche. The registered enrollment target is 66 participants, below the 221-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (70% lower). The trial reports 7 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02453087, a Phase 1 study of Non-Hodgkin's Lymphoma, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 1
Development phase
66 participants
Enrollment target
7
Study locations

Study Summary

This open-label, multicenter, Phase 1/1b study will evaluate the safety, tolerability, and pharmacokinetics of increasing doses of DCDS0780A in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma. In the combination portion of the study, the safety and tolerability of DCDS0780A in combination with rituximab or obinutuzumab will be assessed.

Conditions Studied

Non-Hodgkin's Lymphoma

Interventions

  • DRUG Obinutuzumab
  • DRUG Rituximab
  • DRUG DCDS0780A

Study Locations (7)

California

  • City of Hope National Medical Center - Duarte
  • Stanford Cancer Center - Stanford

Colorado

  • Medical Center of Aurora; Rocky Mountain Cancer Centers - Aurora

District of Columbia

  • Georgetown University Medical Center Lombardi Cancer Center - Washington D.C.

Florida

  • Florida Cancer Specialists - Sarasota (North Catttlemen Rd) - Sarasota

New York

  • New York University Cancer Cen - New York

Oregon

  • Willamette Valley Cancer Ctr - 520 Country Club - Eugene

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2015-08-04
Est. Completion 2019-07-12
Phase Phase 1

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02453087

The ClinicalTrials.gov registry entry for NCT02453087 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (70% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Obinutuzumab is the first listed.

NCT02453087 reports 7 study locations spanning 6 distinct geographic areas - top geographies include California, Colorado, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT02453087 about?

NCT02453087 is a clinical study titled "A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma". This open-label, multicenter, Phase 1/1b study will evaluate the safety, tolerability, and pharmacokinetics of increasing doses of DCDS0780A in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma. In the combination portion of the study, the safety and tolerability of DCDS0780A in...

What is the current status of trial NCT02453087?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2015-08-04. Estimated completion is 2019-07-12.

What conditions does trial NCT02453087 study?

This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma.

What interventions are being tested in trial NCT02453087?

The interventions under investigation include: Obinutuzumab (DRUG), Rituximab (DRUG), DCDS0780A (DRUG).

Who is sponsoring clinical trial NCT02453087?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02453087 being conducted?

This trial has 7 study locations across California, Colorado, District of Columbia, Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Hodgkin's Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Hodgkin's Lymphoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.